Trial Profile

An All-Oral Combination Study of AB-506 and AB-452

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 11 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AB-452 (Primary) ; AB-506 (Primary)
Indications Hepatitis B
Focus Adverse reactions; Therapeutic Use

Most Recent Events

03 Oct 2019 Status changed from planning to withdrawn prior to enrolment, according to an Arbutus Biopharma media release.
13 Jul 2018 New trial record
10 Jul 2018 According to an Arbutus Biopharma media release, the company expects to initiate this trial in 2H 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com